Consensus on precision medicine for metastatic cancers: A report from the MAP conference

Annals of Oncology

Volumn 27, Issue 8, 2016, Pages 1443-1448

  Swanton, C ^a,b   Soria, J C ^c,d   Bardelli, A ^e,f   Biankin, A ^g,h,i   Caldas, C ^j,k,l   Chandarlapaty, S ^m   de Koning, L ⁿ   Dive, C ^o   Feunteun, J ^p   Leung, S Y ^q   Marais, R ^o   Mardis, E R ^r   McGranahan, N ^a   Middleton, G ^s,t   Quezada, S A ^u   Rodon J ^v   Rosenfeld, N ^j   Sotiriou, C ^w   André, Fabrice ^d  

^a THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d Universite Paris Sud   (France)

^e UNIVERSITY OF TURIN   (Italy)

^f CANDIOLO CANCER INSTITUTE   (Italy)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ GLASGOW ROYAL INFIRMARY   (United Kingdom)

^j UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^k UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^l NIHR Cambridge Biomedical Research Centre   (United Kingdom)

^m MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁿ INSTITUT CURIE   (France)

^o UNIVERSITY OF MANCHESTER   (United Kingdom)

^p Gustave Roussy Comprehensive Cancer Institute   (France)

^q UNIVERSITY OF HONG KONG   (Hong Kong)

^r WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^s UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^t UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^u UNIVERSITY COLLEGE LONDON   (United Kingdom)

^v VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^w JULES BORDET INSTITUTE   (Belgium)

more..

Author keywords

Biomarkers; Consensus; Precision medicine

Indexed keywords

CIRCULATING TUMOR DNA; DNA; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; BIOINFORMATICS; BIOPSY TECHNIQUE; BIOTECHNOLOGY; CANCER GENETICS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CONSENSUS; EVIDENCE BASED MEDICINE; GENE AMPLIFICATION; GENE FUNCTION; GENE LOSS; GENETIC HETEROGENEITY; GENETIC SCREENING; GENOMICS; HIGH RISK PATIENT; HUMAN; METASTASIS; MOLECULAR DIAGNOSIS; MOLECULAR GENETICS; NEXT GENERATION SEQUENCING; NONHUMAN; OUTCOME ASSESSMENT; PATIENT SELECTION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEOMICS; STANDARDIZATION; TUMOR SUPPRESSOR GENE; VALIDATION STUDY; VALIDITY; GENETICS; HIGH THROUGHPUT SEQUENCING; MOLECULARLY TARGETED THERAPY; NEOPLASM; PATHOLOGY;

GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PRECISION MEDICINE; PROTEOMICS;

EID: 84985038330     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw192     Document Type: Article

References (29)

1. Santarius T, Shipley J, Brewer D, Stratton MR, Cooper CS. A census of amplified and overexpressed human cancer genes. Nat Rev Cancer. 2010; 10(1): 59-64.
2. Remon J, Planchard D. AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients. Future Oncol 2015; 11(22): 3069-3081.
3. Teutsch SM, Bradley LA, Palomaki GE et al. The evaluation of genomic applications in practice and prevention (EGAPP) initiative: methods of the EGAPP Working Group. Genet Med 2009; 11(1): 3-14.
4. Frampton GM, Fichtenholtz A, Otto GA et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013; 31(11): 1023-1031.
5. Lawrence MS, Stojanov P, Polak P et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499(7457): 214-218.
6. Lavaud P, Andre F. Strategies to overcome trastuzumab resistance in HER2- overexpressing breast cancers: focus on new data from clinical trials. BMC Med 2014; 12: 132.
7. Godbout R, Dryja TP, Squire J, Gallie BL, Phillips RA. Somatic inactivation of genes on chromosome 13 is a common event in retinoblastoma. Nature 1983; 304 (5925): 451-453.
8. Krueger DA, Care MM, Holland K et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010; 363: 1801-1811.
9. Tutt A, Robson M, Garber JE et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376(9737): 235-244.
10. Berger AH, Knudson AG, Pandolfi PP. A continuum model for tumour suppression. Nature 2011; 476(7359): 163-169.
11. Cardoso F, Costa A, Norton L et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol 2014; 25(10): 1871-1888.
12. Andre F, Mardis E, Salm M et al. Prioritizing targets for precision cancer medicine. Ann Oncol 2014; 25(12): 2295-2303.
13. Van Allen EM, Wagle N, Stojanov P et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med 2014; 20(6): 682-688.
14. Dienstmann R, Jang IS, Bot B, Friend S, Guinney J. Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors. Cancer Discov 2015; 5(2): 118-123.
15. Dawson SJ, Tsui DW, Murtaza M et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013; 368(13): 1199-1209.
16. Bettegowda C et al. Detection of circulating tumour DNA in early- and late- stage human malignancies. Sci Transl Med 2014; 6: 224ra224.
17. Diehl F, Schmidt K, Choti MA et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008; 14(9): 985-990.
18. Thierry AR, Mouliere F, El Messaoudi S et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med 2014; 20(4): 430-435.
19. Siravegna G, Mussolin B, Buscarino M et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 2015; 21(7): 795-801.
20. Rothé F, Laes JF, Lambrechts D et al. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol 2014; 25(10): 1959-1965.
21. Couraud S, Vaca-Paniagua F, Villar S et al. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from neversmokers: a proof-of-concept study from BioCAST/IFCT-1002. Clin Cancer Res 2014; 20(17): 4613-4624.
22. Frenel JS, Carreira S, Goodall J et al. Serial next-generation sequencing of circulating cell-free DNA evaluating tumor clone response to molecularly targeted drug administration. Clin Cancer Res 2015; 21(20): 4586-4596.
23. Garcia-Murillas I, Schiavon G, Weigelt B et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med 2015; 7(302): 302ra133.
24. Misale S, Yaeger R, Hobor S et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486(7404): 532-536.
25. Diaz LA, Williams RT, Wu J et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012; 486(7404): 537-540.
26. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366(10): 883-892. Erratum in: N Engl J Med 2012; 367(10): 976.
27. Landau DA, Carter SL, Stojanov P et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013; 152(4): 714-726.
28. De Mattos-Arruda L, Weigelt B, Cortes J et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann Oncol 2014; 25(9): 1729-1735.
29. Michaut M, Chin SF, Majewski I et al. Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. Sci Rep 2016; 6: 18517.